Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on March 12, 2019. The report addresses a specific corporate event regarding the company's listing status on the Nasdaq stock exchange.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes
On March 12, 2019, Trovagene, Inc. announced it has regained compliance with Nasdaq listing requirements. This resolves a prior non-compliance status, though the specific nature of the previous deficiency is not detailed in this excerpt.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the resolution of the listing compliance issue. No unusual items or contingencies are disclosed in this text.
Investor Verification Checklist
- Verify the specific Nasdaq listing rule that was previously violated and the steps taken to achieve compliance.
- Confirm the current trading status of Trovagene, Inc. shares on Nasdaq.
- Review the attached press release (Exhibit 99.1) for additional context on the compliance restoration.
- Note the discrepancy between the request metadata (Cardiff Oncology, Inc.) and the filing content (Trovagene, Inc.).